-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
Study #2014-0800
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
Study Status
Open
Treatment Agent
AG120
Principal Investigator
Hagop Kantarjian
Description
The goal of this clinical research study is to find the highest tolerable dose of AG-120 that can be given to patients with acute myelogenous leukemia (AML) or another type of blood disease (a disease affecting the blood or bone marrow), such as myelodysplastic syndrome (MDS). The safety of this drug will also be studied. This is the first study using AG-120 in humans.
General Information
Disease Group: Hematologic Disorder
Treatment Agent: AG120
Treatment Location: Both at MDACC & and Other Sites
Sponsor: AGIOS Pharmaceuticals
Study Status
IRB Review and Approval Date: 12/15/2014
Recruitment Status: Open
Projected Accrual: 236
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematologic Disorder
Study phase:
Phase I
Physician name:
Hagop Kantarjian
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789